GTOP (GTOP)
All Pro Portfolios with GTOP
All Do-It-Yourself Portfolios with GTOP
- Total Do-It-Yourself Portfolios with GTOP:
- John Ohlson Portfolio 1
- Heywood Jablowme Portfolio 1
- KEG Portfolio 1
- nawzad Portfolio 1
- biotech1
- jschnoebelen Portfolio 1
- louieleslie Portfolio 1
- umrasa Portfolio 1
- RoyAg Portfolio 1
- smallpotatoes
- Toe
- Hot with some dividends
- smartchick Portfolio 1
- PANTERA GROUP 211
- D-Equities
- hueys Portfolio 1
- Rocket Stocks For The Week Of December 24th - December 28th
- show more
- 34
- Nancy Pelosi Stocks
- William T Blanchard - Medical
- Hans01 Portfolio 1
- dotcal604 Portfolio 1
- Research Reports 3-19-07
- SUPRATRADE-QUANTUM 14
- SUPRATRADE- QUANTUM TRUST
- suskie Portfolio 1
- seemedical Portfolio 1
- mungocc Portfolio 1
- massy shok Portfolio 1
- Julio343
- ryukolis Portfolio 1
- JAFO Portfolio 1
- Milwman
- BENITRANS IK
- smallbiz
- News For Selected Stock
- Related stories on theStreet.com
- videos related to etf's
- No videos found
- blogs related to etf's
- No blogs found
Why I Love This Stock |
|
By:Pro |
Date:11 30 -1 |
Genitope (GTOP) was downgraded by RBC Capital Markets from Sector Perform to Underperform. |
|
Not yet rated
Rate now:
|
|
By:hueys |
Date:12 08 07 |
Cancer research |
|
Not yet rated
Rate now:
|
|
By:smartchick |
Date:09 27 07 |
spec |
|
Not yet rated
Rate now:
|
|
By:sallysgspot |
Date:09 07 07 |
IF!! Lupus trials impess FDA |
|
Not yet rated
Rate now:
|
|
By:vikasd |
Date:04 28 07 |
Cancer vaccine |
|
Not yet rated
Rate now:
|
|
By:Pro |
Date:11 30 -1 |
Downgraded by Brean Murray from Hold to Sell |
|
Not yet rated
Rate now:
|
|
By:Barrons |
Date:03 17 07 |
Fourth-quarter loss exceeded expectations, but the company has sufficient cash to fund operations through the end of 2007. We believe the driver remains the Phase III MyVax data in follicular non-Hodgkins lymphoma that are expected in Q407. We remain cautious on the outcome of this trial. Given the binary nature of the data on GTOP's stock, we maintain our Hold rating. |
|
Not yet rated
Rate now:
|
|
Why I Hate This Stock |
|
By:investor1990 |
Date:05 17 07 |
Adam Feuerstein answers questions about Genitope, Immunogen, and Nymox in his Biotech-Stock mailbag (http://www.thestreet.com/_tscs/newsanalysis/biotech/10354735.html). This is the only reason I added these stocks to this portfolio. Mainly to track to see if he is right. A reader asked if Genitope is the next Dendreon. Feuerstein thinks not, but sees competition with Genetech's non-Hodgkin's lymphoma drug. He doesn't see much hope for Immunogen either. And he doesn't like Nymox, instead recommending Spectrum and Aeterna Zentaris. So these stocks go into the Favorite column, and the others into Least Favorite. We'll see where they are in 6 months. |
|
Not yet rated
Rate now:
|
|
Date:01 03 07 |
|
Where's the earnings? |
|
Not yet rated
Rate now:
|
|